York Trials Unit, ARRC Building, Department of Health Sciences, University of York, York, UK.
Centre for Health Economics, University of York, York, UK.
Eur J Health Econ. 2020 Jun;21(4):621-634. doi: 10.1007/s10198-020-01160-5. Epub 2020 Feb 5.
A centralised approach to health technology assessment (HTA) may facilitate optimal use of HTA resources. A regional approach may increase the chances of local implementation of recommendations. This study aimed to compare assessment procedures in England (centralised HTA approach) with Spain (regional HTA approach) discussing key challenges and opportunities from both approaches.
We compared technology assessments of anticancer medicines in the two jurisdictions from 2008 to 2015. To assess the implementation of HTA recommendations, we assessed trends in medicine usage using regression methods. We used IQVIA data, from 2011 to 2016, for a sample of 11 medicines. We used CatSalut data from Catalonia to assess the implementation of local recommendations.
In England, 66 assessments were undertaken by the National Institute for Health and Care Excellence (NICE), using a standardised methodology. In Spain, there were 79 reports undertaken by a range of bodies using a shared process and coordinated through the GENESIS collaboration; the assessment methods used varied substantially. Overall, the recommendations in the two jurisdictions were similar. Regression analyses indicate that where there is a positive recommendation by HTA bodies, the usage of the medicine responds most strongly (p < 0.001) in Catalonia (4.892), followed by England (3.120) and Spain (1.693).
This study suggests that medicine utilisation does respond to the positive recommendations of HTA bodies. However, if HTA capacity is organised primarily regionally, considerable effort may be required in coordination, to ensure consistent and rigorous assessments and adequate implementation of HTA findings.
集中式的卫生技术评估(HTA)方法可能有助于优化 HTA 资源的利用。区域性方法可能会增加建议在当地实施的机会。本研究旨在比较英国(集中式 HTA 方法)和西班牙(区域性 HTA 方法)的评估程序,讨论两种方法的主要挑战和机遇。
我们比较了 2008 年至 2015 年这两个司法管辖区的抗癌药物的技术评估。为了评估 HTA 建议的实施情况,我们使用回归方法评估了药物使用的趋势。我们使用了 IQVIA 从 2011 年到 2016 年的数据,对 11 种药物进行了抽样。我们使用 CatSalut 数据评估了当地建议的实施情况。
在英国,国家卫生与保健优化研究所(NICE)进行了 66 项评估,使用了标准化的方法。在西班牙,有 79 份报告由一系列机构使用共享的流程和通过 GENESIS 合作进行协调完成;所使用的评估方法有很大的不同。总体而言,两个司法管辖区的建议相似。回归分析表明,当 HTA 机构给出积极的建议时,药物的使用反应最强(p<0.001),在加泰罗尼亚(4.892),其次是英国(3.120)和西班牙(1.693)。
本研究表明,药物的使用确实对 HTA 机构的积极建议有反应。然而,如果 HTA 能力主要是区域性的,那么在协调方面可能需要付出相当大的努力,以确保评估的一致性和严谨性,并充分实施 HTA 的结果。